GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Travere Therapeutics Inc (NAS:TVTX) » Definitions » Debt-to-Asset

TVTX (Travere Therapeutics) Debt-to-Asset : 0.80 (As of Sep. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Travere Therapeutics Debt-to-Asset?

Travere Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $73.9 Mil. Travere Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $328.5 Mil. Travere Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $504.4 Mil. Travere Therapeutics's debt to asset for the quarter that ended in Sep. 2024 was 0.80.


Travere Therapeutics Debt-to-Asset Historical Data

The historical data trend for Travere Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Travere Therapeutics Debt-to-Asset Chart

Travere Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.34 0.40 0.34 0.61 0.51

Travere Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.51 0.61 0.73 0.80

Competitive Comparison of Travere Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Travere Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Travere Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Travere Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Travere Therapeutics's Debt-to-Asset falls into.



Travere Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Travere Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(4.909 + 399.875) / 788.913
=0.51

Travere Therapeutics's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(73.896 + 328.538) / 504.41
=0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Travere Therapeutics  (NAS:TVTX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Travere Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Travere Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Travere Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Executives
Sandra Calvin officer: VP, Corp Controller and CAO 3611 VALLEY CENTER DRIVE, SUITE 300, SAN DIEGO CA 92130
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Jeffrey A Meckler director 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
Jula Inrig officer: Chief Medical Officer C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
William E. Rote officer: Senior Vice President, R&D C/O RETROPHIN, INC., 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Christopher R. Cline officer: Chief Financial Officer C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO CA 92130
Eric M Dube director, officer: Chief Executive Officer 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Peter Heerma officer: Chief Commercial Officer C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Elizabeth E Reed officer: SVP, GC & Corporate Secretary 9050 CAMINO SANTA FE, SAN DIEGO CA 92121
Laura Clague officer: Chief Financial Officer 370 PARK RANCH PLACE, ESCONDIDO CA 92025
Steve Aselage director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Brinkley Ruth Williams director C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Noah L. Rosenberg officer: Chief Medical Officer C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Neil F. Mcfarlane officer: Chief Operating Officer C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130